# Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults

> **NCT07675629** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Worcester HIV Vaccine** · enrollment: 126 (estimated)

## Conditions studied

- HIV Prevention

## Interventions

- **BIOLOGICAL:** PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C))
- **BIOLOGICAL:** PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E))
- **BIOLOGICAL:** Alhydrogel adjuvant
- **BIOLOGICAL:** GLA-SE adjuvant
- **BIOLOGICAL:** Placebo for DNA Vaccines, Protein Vaccines and Adjuvants

## Key facts

- **NCT ID:** NCT07675629
- **Lead sponsor:** Worcester HIV Vaccine
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2028-08-31
- **Final completion:** 2029-08
- **Target enrollment:** 126 (ESTIMATED)
- **Last updated:** 2026-06-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07675629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07675629, "Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07675629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*